Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ALDX

ALDX - Aldeyra Therapeutics Inc Stock Price, Fair Value and News

$5.42-0.12 (-2.17%)
Market Closed

Price Targets

ALDX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALDX Price Action

Last 7 days

8.6%

Last 30 days

4.8%

Last 90 days

7.8%

Trailing 12 Months

3.6%

ALDX RSI Chart

ALDX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALDX Valuation

Market Cap

326.1M

Price/Earnings (Trailing)

-7.55

EV/EBITDA

-4.25

Price/Free Cashflow

-8.14

MarketCap/EBT

-5.13

ALDX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

ALDX Fundamentals

ALDX Earnings

Earnings (TTM)

-43.2M

Earnings Growth (Yr)

49.13%

Earnings Growth (Qtr)

21.28%

ALDX Profitability

Return on Equity

-87.71%

Return on Assets

-55.52%

Free Cashflow Yield

-12.29%

ALDX Investor Care

Shares Dilution (1Y)

1.03%

Diluted EPS (TTM)

-0.73

About Aldeyra Therapeutics Inc

ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
 CEO
 WEBSITEaldeyra.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES15

Aldeyra Therapeutics Inc Frequently Asked Questions

ALDX is the stock ticker symbol of Aldeyra Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Aldeyra Therapeutics Inc is 326.08 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ALDX's fair value in chart for subscribers.

The fair value guage provides a quick view whether ALDX is over valued or under valued. Whether Aldeyra Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aldeyra Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALDX.

In the past 10 years, Aldeyra Therapeutics Inc has provided 0.012 (multiply by 100 for percentage) rate of return.